Enanta Pharmaceuticals to Participate in December Investor Conferences
November 19 2021 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, will
participate in two virtual investor conferences in December:
- Evercore ISI 4th Annual HealthCONx Conference, December 1, 2021
with a fireside chat at 10:30 a.m. ET.
- Piper Sandler 33rd Annual Healthcare Conference, December 2,
2021. Company pre-recorded fireside chat will become available to
registered conference attendees on Monday, November 29, 2021 at
10:00 a.m. ET.
A webcast of the each event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. Replays of the webcasts will be
available following the presentations and will be archived for at
least 14 days.
About Enanta Enanta is using its robust, chemistry-driven
approach and drug discovery capabilities to become a leader in the
discovery and development of small molecule drugs for the treatment
of viral infections and liver diseases. Enanta’s research and
development efforts have produced clinical candidates currently in
development for the following disease targets: respiratory
syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2
(COVID-19). Enanta is also conducting research in human
metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211119005117/en/
Investor Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024